Navigation Links
New Review of Novel Intranasal Delivery of Sumatriptan as a Route to Rapid and Sustained Relief in the Acute Treatment of Migraine
Date:11/17/2016

LONDON, November 17, 2016 /PRNewswire/ --

Deborah I Friedman, US Neurology , 2016;12(2):84-9: https://doi.org/10.17925/USN.2016.12.02.84

     (Logo: http://photos.prnewswire.com/prnh/20151014/276718LOGO)
Published recently in US Neurology, the peer-reviewed journal from touchNEUROLOGY, Deborah I Friedman discusses a new treatment in migraine. This condition remains a common debilitating condition that exerts a high social and economic burden worldwide. Despite the widespread availability of various medications for migraine, many patients are dissatisfied with their treatment. Rapid and effective treatment at an early stage in an attack is vital in migraine to prevent central sensitization leading to attacks that are difficult to treat. Most migraineurs prefer oral medications but this is not always the most rapid or efficient route into the bloodstream. Intranasal administration of migraine treatment provides a rapid, convenient and reliable alternative to oral and other routes. AVP-825 is an intranasal medication delivery system approved by the US Food and Drug Administration in January 2016 as ONZETRA™ Xsail™ (sumatriptan nasal powder [Avanir Pharmaceuticals, Aliso Viejo, CA]) for the acute treatment of migraine with or without aura in adults. AVP-825 contains low dose sumatriptan powder and takes advantage of some unique aspects of the nasal anatomy to confer rapid pain relief in the acute treatment of migraine. In two Phase III trials, AVP-825 was well tolerated and showed significantly faster migraine pain relief and relief from other symptoms including photophobia, phonophobia, and nausea than placebo or oral sumatriptan. This benefit was achieved with substantially lower drug exposure than oral sumatriptan. Additional analyses of data from the Phase III trials show that significantly more patients with migraine receiving AVP-825 reported clinically meaningful relief, sustained relief, pain freedom, lower migraine-related disability and more consistent relief across multiple attacks than those receiving oral sumatriptan. The rapid and sustained action of AVP-825 and its convenience creates the potential for this unique treatment to reduce the burden of migraine in many patients.

The full peer-reviewed, open-access article is available here:

https://doi.org/10.17925/USN.2016.12.02.84

Disclosure: Deborah I Friedman is a consultant for Allergan, Avanir, Supernus, Teva Pharmaceuticals, Eli Lilly, Zosano, and Alder Biopharmaceuticals. She is a speaker for Avanir, Supernus, Teva Pharmaceuticals and has received research support from Merck, Autonomic Technologies, Inc., and Eli Lilly.

Note to the Editor

touchNEUROLOGY (a division of Touch Medical Media) publishes

US Neurology, a peer-reviewed, open access, bi-annual journal specialising in the publication of balanced and comprehensive review articles written by leading authorities to address the most important and salient developments in the field of neurology. The aim of these reviews is to break down the high science from 'data-rich' primary papers and provide practical advice and opinion on how this information can help physicians in the day to day clinical setting. Practice guidelines, symposium write-ups, case reports, and original research articles are also featured to promote discussion and learning amongst physicians, clinicians, researchers and related healthcare professionals.

http://www.touchNEUROLOGY.com

For inquires please contact:
Carla Denaro - Managing Editor
managingeditor@touchmedicalmedia.com
Providing practical opinion to support best practice for busy healthcare professionals


'/>"/>
SOURCE touchNEUROLOGY.com
Copyright©2016 PR Newswire.
All rights reserved


Related medicine technology :

1. Insomnia Pipeline Landscape and Therapeutics Development Market Review H2 2016
2. Viral Conjunctivitis Pipeline Drugs Market: (FST-100 and APD-209): Industry Analysis, Pipeline Review, Patent Analysis, and Forecast 2020 - 2023
3. Degenerative Scoliosis Global Clinical Trials Review, H2, 2016
4. Novartis drug PKC412 (midostaurin) granted FDA Priority Review for newly-diagnosed FLT3-mutated AML and advanced systemic mastocytosis
5. World Heart Federation Previews Global Roadmap to Tackle Cholesterol
6. Novel Intraocular Pressure-Lowering Agent, Latanoprostene Bunod, Under Review
7. Emmaus New Drug Application for Sickle Cell Disease Accepted for Review by FDA
8. Biotechnology Stocks Under Review - Eleven Biotherapeutics, Relypsa, Galena Biopharma, and Amgen
9. Market of Rett Syndrome Pipeline Reviewed of 14 Companies and 23 Drug Profiles
10. A New Review Defines Essential Components of Comprehensive Care of Patients With Spastic Paresis and the Need for a Long-Term Commitment
11. New Expert Review of Adaptive Servo-Ventilation
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/10/2017)... GAITHERSBURG, Md. , July 10, 2017 ... in non-animal test methods, is the recipient of a ... by the PETA International Science Consortium. The device, which ... be used to expose human lung cells to airborne ... lung. IIVS will use the VITROCELL® system for testing ...
(Date:7/6/2017)... the nutrition division of Diplomat Specialty Infusion Group, is celebrating a decade ... To celebrate its anniversary, ThriveRx recently launched a redesigned website at ... improved organization to create the best user experience for consumers and health ... Diplomat ... "We,ve made several great strides throughout the past ...
(Date:7/5/2017)... 5, 2017   BioLife Solutions , Inc. (NASDAQ: ... marketer of proprietary clinical grade cell and tissue ... ("BioLife"), today announced that it has reached an agreement ... largest shareholder, to modify its existing credit facility effective ... modification, WAVI agreed to exchange its existing $4.25 million ...
Breaking Medicine Technology:
(Date:7/25/2017)... Irving, Texas (PRWEB) , ... July 25, 2017 ... ... and fastest growing ATM provider in the United States, today announced its partnership ... to financial institutions. , The foundation of the solution lies within Hyosung’s ...
(Date:7/25/2017)... ... July 25, 2017 , ... SignatureCare Emergency Center – South ... TX area 24 Hours a day. , The Emergency Room opened ... “We’ve been open four months now and things are running smoothly,” said Aaron Braun, ...
(Date:7/24/2017)... , ... July 24, 2017 , ... SignatureCare Emergency ... will be awarded for the fall semester to a deserving student. Get your ... Spring 2017 scholarship was awarded to Mariana Castillo who is a nursing student at ...
(Date:7/24/2017)... ... July 24, 2017 , ... A ... destroyed the construction site and threatened numerous homes and businesses nearby, causing some ... on NBCLosAngeles.com. Los Angeles Area consulting firm Fire Protection Group, Inc. notes ...
(Date:7/24/2017)... ... July 24, 2017 , ... Axiad IDS , a ... it has partnered with WALLIX to expand its solution to help government ... There are a number of ways to address the authentication requirements within NIST ...
Breaking Medicine News(10 mins):